SequelSEC

Cannabis Bioscience International Holdings, Inc. CBIH

Services-Commercial Physical & Biological Research · CIK 0001411057 · Fiscal year ends 0531

AnnualQuarterlyTTM
Revenue
$11.20K
Fiscal year ended 2026-02-28
Operating income
-$93.26K
Fiscal year ended 2026-02-28
Free cash flow
Unavailable
Fiscal year ended 2026-02-28

Cannabis Bioscience International Holdings, Inc. (CBIH) reported revenue of $11.20K and net income of -$103.93K for the fiscal year ended 2026-02-28. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Cannabis Bioscience International Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

Cannabis Bioscience International Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Revenue$11.20K$53.27K$24.20K$34.96K$14.93K$74.25K$178.89K$75.86K$36.41K$63.75K
Cost of revenue$3.04K$10.50K$8.14K$4.54K$19.40K$7.80K$8.36K$9.88K$11.81K$15.09K
Gross profit$8.16K$42.77K$16.06K$30.41K-$4.46K$66.44K$170.52K$65.98K$24.60K$48.66K
Operating income-$93.26K-$95.88K-$74.78K-$134.90K-$129.23K-$59.63K-$97.60K-$29.63K-$159.97K-$94.51K
Net income-$103.93K-$116.97K-$82.64K-$211.74K-$181.24K-$79.53K-$76.30K-$135.94K-$209.19K-$124.43K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 11.63Bshares 11.63Bshares 11.63BUnavailableshares 10.73Bshares 10.50Bshares 10.46BUnavailableshares 10.37Bshares 10.33B
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.00$-0.00$-0.00Unavailable$-0.00$-0.00$-0.00Unavailable$-0.00$-0.00
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$26.83K$30.97K$23.31K-$49.69K$50.17K$40.13K$61.30K$9.75K$25.29K$8.41K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Cannabis Bioscience International Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$1.54K$22.13K$18.94K$31.88K$14.89KUnavailable$46.28K$57.16K$93.97K$101.84K
Current assets$1.54K$22.13K$18.94K$29.08K$3.79KUnavailable$18.74K$21.49K$18.43K$19.74K
Total liabilities$1.47M$1.39M$1.27M$1.20M$1.24MUnavailable$1.10M$1.14M$1.07M$943.73K
Current liabilities$1.22M$1.14M$1.02M$945.96K$970.06KUnavailable$852.10K$881.91K$801.05K$660.31K
Total equity incl. NCI-$1.47M-$1.36M-$1.25M-$1.16M-$1.23M-$1.13M-$1.06M-$1.08M-$976.08K-$841.89K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$1.27K$21.81K$8.97K$6.38K$2.64KUnavailable$17.18K$20.14K$17.04K$19.40K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$249.50K$249.50K$249.50K$249.50K$249.50KUnavailable$249.50K$249.36K$249.50K$249.50K
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Cannabis Bioscience International Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Operating cash flow-$14.60K-$5.49K-$103.71K-$144.31K-$82.81K-$72.09K-$30.41K-$174.44K-$9.08K-$221.25K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flowUnavailableUnavailableUnavailable$156.72KUnavailableUnavailable$30.63K$174.40K$9.53K$216.84K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$457Unavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Cannabis Bioscience International Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-282025-11-302025-08-312025-05-312025-02-282024-11-302024-08-312024-05-312024-02-292023-11-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin72.8%80.3%66.4%87.0%-29.9%89.5%95.3%87.0%67.6%76.3%
Operating margin-832.3%-180.0%-309.0%-385.9%-865.5%-80.3%-54.6%-39.1%-439.3%-148.3%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.00x0.02x0.02x0.03x0.00xUnavailable0.02x0.02x0.02x0.03x
Revenue YoY growth-25.0%-28.3%-86.5%-53.9%-59.0%16.5%145.7%63.5%-29.0%-22.8%
Net margin-927.6%UnavailableUnavailable-605.7%-1213.9%UnavailableUnavailable-179.2%-574.5%Unavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CBIH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-04-16View SEC filing
10-Q · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-22View SEC filing
10-K · Filed 2025-09-22View SEC filing
10-Q/A · Filed 2025-05-09View SEC filing
10-Q · Filed 2024-10-21View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.